^
    over3years
    #OncoAlert Online @CCR_AACR is the phase I study of osimertinib and ramucirumab in #EGFR T790M mutant NSCLC by @HelenaYu923 @Piuchagarrido @dplanchard #LCSM https://t.co/apX7bYCTKH (@StephenVLiu)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR mutation + EGFR T790M
    |
    Tagrisso (osimertinib)
    over3years
    The 2nd Annals of Oncology podcast is out on @SoundCloud ! https://t.co/GFJbzv2yvt Listen to Pr Mok @TonyMok9 discussing the OS analysis of AURA3 investigating Osimertinib in NSCLC with EGFR T790M mutations. You can find the manuscript here: https://t.co/kim3N4SF3T #LCSM (@Annals_Oncology)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR mutation + EGFR T790M
    |
    Tagrisso (osimertinib)
    over3years
    Promising perspectives for EGFR mutant #lcsm #ESMO20 with 4th generation EGFR TKI that can block triple mutant EGFR/T790M/C797S (@jsoriamd)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR C797S • EGFR mutation + EGFR T790M • EGFR mutation + EGFR T790M + EGFR C797S
    over3years
    1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L) (@VamsiVelcheti)
    Clinical • P2 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR mutation + EGFR T790M
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib)